Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2021-02-03 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
西部证券股份有限公司关于圣湘生物科技股份有限公司对外投资暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities firm (西部证券股份有限公司) acting as a sponsor for 圣湘生物科技股份有限公司 regarding a specific related-party transaction and external investment. It includes comprehensive information about the investment, the parties involved, the transaction structure, approvals by the board, independent directors' opinions, risk analysis, and sponsor's final opinion. The document is not a brief announcement but a full verification and review report related to a specific transaction. It does not contain financial statements or earnings data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or announcement of a report publication. The content focuses on the audit and verification of a related-party transaction and investment, which aligns with the category of Audit Report / Information (AR). The document length (4714 characters) and detailed content support this classification with high confidence. Q1 2021
2021-02-03 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司募集资金置换预先投入募投项目及已支付发行费用的自筹资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of raised funds by a company (圣湘生物科技股份有限公司) for replacing self-raised funds previously invested in projects and issuance expenses. It references regulatory guidelines, approval by the board and supervisory committee, independent directors' opinions, and an auditor's verification report. The document is focused on the compliance and procedural correctness of the use of raised funds, not on presenting financial statements or results. It is a regulatory compliance and verification report related to fundraising and fund usage, not an annual or interim financial report, earnings release, or capital update. The document length is 4401 characters, which is relatively short and focused on a specific regulatory verification. This fits best under Regulatory Filings (RNS) as it is a compliance and verification announcement rather than a full financial report or capital update.
2021-02-03 Chinese
关于对外投资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding an external investment and related party transaction. It details the company's plan to invest in a joint venture with an affiliated party, including investment amounts, ownership percentages, and governance structure. The document includes independent directors' opinions, board approval details, and a sponsor's verification opinion. It does not contain financial statements or comprehensive financial performance data. The document is primarily an announcement of a corporate transaction involving related parties, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes involving investments and related party transactions.
2021-01-29 Chinese
关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 圣湘生物科技股份有限公司 regarding the use of raised funds to replace self-raised funds previously invested in projects and paid issuance expenses. It details the approval by the board and supervisory committee, references regulatory approvals from the China Securities Regulatory Commission, and includes opinions from independent directors, the supervisory board, the accounting firm, and the sponsor institution. The document is about the company's capital management and use of fundraising proceeds, specifically the replacement of self-raised funds with raised funds. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, proxy, or remuneration report. The document is a formal announcement about capital use and financing activities related to fundraising. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters but contains detailed information about the capital replacement, not just a brief report publication announcement. Hence, CAP is the most appropriate classification.
2021-01-29 Chinese
关于购买资产的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 圣湘生物科技股份有限公司 regarding the purchase of assets, specifically the acquisition of 100% equity in 湖南海兴电器有限责任公司, a subsidiary of 杭州海兴电力科技股份有限公司. It details the transaction amount, the nature of the transaction, the approval by the board of directors, and the impact on the company. The document includes financial data related to the target company but does not contain comprehensive financial statements or detailed financial performance analysis. It is a formal announcement of a capital transaction (asset purchase) rather than a full financial report or earnings release. The document is about a financing/capital structure update due to the acquisition. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-01-29 Chinese
第一届监事会2021年第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the use of raised funds to replace previously invested funds and payment of issuance expenses. It includes details about the meeting attendance, the resolution passed, and voting results. There is no financial statement or detailed financial report content, but rather a corporate governance and supervisory board decision announcement. It is not an annual report, audit report, or earnings release. It is not a call transcript or investor presentation. The document is a formal announcement of a board/management decision, specifically from the supervisory board, which fits best under Board/Management Information (MANG). The document length is short and it is not announcing a report publication, so it is not RPA. Therefore, the classification is MANG with high confidence.
2021-01-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.